CTAD first began in 2008 and is the only meeting focused entirely on Alzheimer’s Disease Therapeutic Trials with key leaders in AD research getting together and forming partnership with the objective of speeding the development of effective treatments to fight the disease.
As well as important therapeutic trial results, clinical trial teams from around the world will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.
TauRx will have a dedicated meeting room at the event, and we look forward to connecting with everyone there.
